US Patent

US8293756 — Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate

Formulation · Assigned to Novartis AG · Expires 2027-09-25 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition, specifically capsules, containing granules of nilotinib or a salt thereof with one or more acceptable excipients.

USPTO Abstract

A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.

Drugs covered by this patent

nilotinib-hydrochloride (Nilotinib Hydrochloride) · Jan Beumer

Patent Metadata

Patent number: US8293756
Jurisdiction: US
Classification: Formulation
Expires: 2027-09-25
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.